

May 3, 2022



# TC BioPharm Invited to Present at LD Micro Conference

EDINBURGH, Scotland, May 3, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that the company will participate at the upcoming 2022 LD Micro Invitational, a prominent 3-day investor conference, at the Four Seasons Hotel Westlake Village on June 7th-9th, 2022.

The LD Micro Conference will host approximately 200 companies from all over the world. Each company will present for 25 minutes each, and finalize their exhibition with private meetings. For more information or to coordinate a meeting with TC BioPharm's management, please contact [IR@tcbiopharm.com](mailto:IR@tcbiopharm.com)

**Event:** The LD Micro Invitational

**Date:** Tuesday, June 7th - Thursday, June 9th, 2022

**Location:** Four Seasons Westlake Village

## About TC BioPharm (Holdings) PLC


TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and viral infections with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmniImmune® in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.

## Forward Looking Statements

This press release may contain statements of a forward-looking nature relating to future

events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

 View original content: <https://www.prnewswire.com/news-releases/tc-biopharm-invited-to-present-at-ld-micro-conference-301537604.html>

SOURCE TC BioPharm